Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions
In addition, exendin 4 exerted renoprotective effects in animal models through inhibition of nuclear factor-B (NF-B) activity in the kidney, and elevated NF-B activity is known to contribute to the crosstalk between inflammation and oxidative stress 96
Theres a good chance youll need to stay on the medications forever, says Dr
When GHK-Cu peptides and vitamin C are used together in the same routine, their potent effects can be diminished
Obesity Research
A combination of strength training and cardiovascular exercise works best